Role of TNFRSF1B polymorphisms in the response of Crohn's disease patients to infliximab

Human Immunology

Volumn 75, Issue 1, 2014, Pages 71-75

  Medrano, L M ^a   Taxonera, C ^a   Marquez A ^b   Barreiro de Acosta, M ^c   Gomez Garcia M ^d   Gonzalez Artacho C ^d   Perez Calle J L ^e   Bermejo, F ^f   Lopez Sanroman A ^g   Martin Arranz M D ^h   Gisbert, J P ⁱ   Mendoza, J L ^a   Martin J ^b   Urcelay, E ^a   Nunez C ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^c Instituto de Salud Carlos III   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^e HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^f HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^g HOSPITAL RAMÓN Y CAJAL   (Spain)

^h HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

ⁱ Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY 1B; UNCLASSIFIED DRUG;

AGE; ARTICLE; CHI SQUARE TEST; CLINICAL FEATURE; CONTROLLED STUDY; CROHN DISEASE; DISEASE DURATION; FISHER EXACT TEST; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HUMAN; IMMUNITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REMISSION; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; TREATMENT RESPONSE;

ADULT; ALLELES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; CROHN DISEASE; FEMALE; GENE FREQUENCY; GENOTYPE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84890146720     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2013.09.017     Document Type: Article

References (19)

1. Abraham C., Cho J.H. Inflammatory bowel disease. N Engl J Med 2009, 361:2066-2078.
2. Franke A., McGovern D.P., Barrett J.C., Wang K., Radford-Smith G.L., Ahmad T., et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 2010, 42:1118-1125.
3. Monteleone G., Pallone F., MacDonald T.T. Emerging immunological targets in inflammatory bowel disease. Curr Opin Pharmacol 2011, 11:640-645.
4. Van Assche G., Rutgeerts P. Anti-TNF agents in Crohn's disease. Expert Opin Investig Drugs 2000, 9:103-111.
5. Rutgeerts P., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004, 126:402-413.
6. Sands B.E., Anderson F.H., Bernstein C.N., Chey W.Y., Feagan B.G., Fedorak R.N., et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004, 350:876-885.
7. Chaudhary R., Ghosh S. Prediction of response to infliximab in Crohn's disease. Dig Liver Dis 2005, 37:559-563.
8. Morita C., Horiuchi T., Tsukamoto H., Hatta N., Kikuchi Y., Arinobu Y., et al. Association of tumor necrosis factor receptor type II polymorphism 196R with systemic lupus erythematosus in the Japanese: molecular and functional analysis. Arthritis Rheum 2001, 44:2819-2827.
9. Puga I., Lainez B., Fernandez-Real J.M., Buxade M., Broch M., Vendrell J., et al. A polymorphism in the 3' untranslated region of the gene for tumor necrosis factor receptor 2 modulates reporter gene expression. Endocrinology 2005, 146:2210-2220.
10. Till A., Rosenstiel P., Krippner-Heidenreich A., Mascheretti-Croucher S., Croucher P.J., Schafer H., et al. The Met-196 -> arg variation of human tumor necrosis factor receptor 2 (TNFR2) affects TNF-alpha-induced apoptosis by impaired NF-kappaB signaling and target gene expression. J Biol Chem 2005, 280:5994-6004.
11. Matsukura H., Ikeda S., Yoshimura N., Takazoe M., Muramatsu M. Genetic polymorphisms of tumour necrosis factor receptor superfamily 1A and 1B affect responses to infliximab in Japanese patients with Crohn's disease. Aliment Pharmacol Ther 2008, 27:765-770.
12. Mascheretti S., Hampe J., Kuhbacher T., Herfarth H., Krawczak M., Folsch U.R., et al. Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn's disease treated with infliximab. Pharmacogenomics J 2002, 2:127-136.
13. Pierik M., Vermeire S., Steen K.V., Joossens S., Claessens G., Vlietinck R., et al. Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab. Aliment Pharmacol Ther 2004, 20:303-310.
14. Steenholdt C., Enevold C., Ainsworth M.A., Brynskov J., Thomsen O.O., Bendtzen K. Genetic polymorphisms of tumour necrosis factor receptor superfamily 1b and fas ligand are associated with clinical efficacy and/or acute severe infusion reactions to infliximab in Crohn's disease. Aliment Pharmacol Ther 2012, 36:650-659.
15. Steenholdt C., Brynskov J., Thomsen O.O., Munck L.K., Fallingborg J., Christensen L.A., et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut 2013, [Epub ahead of print].
16. Lennard-Jones J.E. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989, 170:2-6. [discussion 16-19].
17. Harvey R.F., Bradshaw J.M. A simple index of Crohn's-disease activity. Lancet 1980, 1:514.
18. Miheller P., Lakatos P.L., Horvath G., Molnar T., Szamosi T., Czegledi Z., et al. Efficacy and safety of infliximab induction therapy in Crohn's disease in Central Europe - a Hungarian nationwide observational study. BMC Gastroenterol 2009, 9:66.
19. Arijs I., Quintens R., Van Lommel L., Van Steen K., De Hertogh G., Lemaire K., et al. Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's disease. Inflamm Bowel Dis 2010, 16:2090-2098.